| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
TNFα (IC50 = 22 µM)
SPD-304 targets tumor necrosis factor α (TNF-α), a pro-inflammatory cytokine involved in various inflammatory and autoimmune diseases (e.g., rheumatoid arthritis, inflammatory bowel disease). By binding to the TNF-α trimer, it promotes the dissociation of the trimer, thereby blocking the interaction of TNF-α with its receptor TNFR1. This inactivates the cytokine and inhibits its downstream signaling (e.g., NF-κB activation). |
|---|---|
| ln Vitro |
SPD304 (2 μM) significantly rescues the survivability of aHSCs, reduces the production of lipid hydroxides, and increased intracellular GSH. The co-treatment of GA (75 μM) and SPD304 (2 μM) downregulates TRADD almost 2-fold (w/o inhibitor vs. w/ inhibitor) and pRIP3 1.4-fold compared to GA alone, and promotes caspase 8 activation[4].
In vitro, SPD-304 (2 μM) significantly rescues the survivability of activated hepatic stellate cells (aHSCs), reduces the production of lipid hydroxides, and increases intracellular GSH. It prevents the binding of TNF-α to TNFR1 with an IC50 of 22 µM. Its activity is characterized by inhibition of TNF-α-induced cellular responses. |
| ln Vivo |
SPD304 cannot be used in vivo due to its high toxicity[3].
In vivo, SPD-304 has been studied for its potential to inhibit TNF-α activity. However, detailed in vivo efficacy data for specific disease models (e.g., arthritis, colitis) are limited. The compound is primarily used as a research tool for studying TNF-α biology and inflammation, rather than a therapeutic candidate. |
| Enzyme Assay |
In vitro binding assays for SPD-304 typically measure its ability to inhibit the binding of TNF-α to TNFR1. These assays can be performed using ELISA-based competition assays (where TNF-α is coated, and TNFR1-Fc is added with the compound) or surface plasmon resonance (SPR) to quantify the interaction between TNF-α and TNFR1 in the presence of the compound.
|
| Cell Assay |
In vitro cellular assays for SPD-304 involve treating cells (e.g., HEK293 or HeLa cells expressing TNFR1) with the compound and measuring its effects on TNF-α-induced signaling, such as NF-κB activation (by reporter gene assay) or cytokine production (by ELISA). The compound's ability to rescue cell viability and reduce oxidative stress has also been demonstrated in hepatic stellate cells.
|
| Animal Protocol |
In vivo animal models for SPD-304 may include models of inflammatory diseases, such as collagen-induced arthritis (CIA) or dextran sulfate sodium (DSS)-induced colitis, to evaluate its efficacy in inhibiting TNF-α. However, detailed animal protocol information is limited. The compound is primarily used as a research tool in acute inflammation models.
|
| ADME/Pharmacokinetics |
SPD-304 has a molecular formula of C32H32F3N3O2 and a molecular weight of 547.61 g/mol. Its chemical name is 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one. It is a selective TNF-α inhibitor and is typically stored as a powder at -20°C, soluble in DMSO.
|
| Toxicity/Toxicokinetics |
SPD-304 is a TNF-α inhibitor with a well-characterized mechanism of action. As with any experimental compound, potential toxicity should be evaluated in preclinical studies. It is for research use only and is not approved for human therapeutic use. Adverse effects may include immunosuppression.
|
| References | |
| Additional Infomation |
SPD-304 is a novel, potent, and selective inhibitor of tumor necrosis factor α (TNF-α). It prevents the binding of TNF-α to TNFR1 with an IC50 of 22 µM. The compound is for research use only and is not approved for human therapeutic use.
|
| Molecular Formula |
C32H32F3N3O2
|
|---|---|
| Molecular Weight |
547.6106
|
| Exact Mass |
547.244
|
| Elemental Analysis |
C, 70.19; H, 5.89; F, 10.41; N, 7.67; O, 5.84
|
| CAS # |
869998-49-2
|
| Related CAS # |
SPD304 dihydrochloride;1049741-03-8
|
| PubChem CID |
5327044
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
589.2±50.0 °C at 760 mmHg
|
| Flash Point |
310.2±30.1 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.583
|
| LogP |
8.23
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
40
|
| Complexity |
910
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C(CN(CCN(CC2C3C(=CC=CC=3)N(C3C=C(C(F)(F)F)C=CC=3)C=2)C)C)=COC2C1=CC(C)=C(C)C=2
|
| InChi Key |
JZNXLPPJRFFECJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C32H32F3N3O2/c1-21-14-28-30(15-22(21)2)40-20-24(31(28)39)18-37(4)13-12-36(3)17-23-19-38(29-11-6-5-10-27(23)29)26-9-7-8-25(16-26)32(33,34)35/h5-11,14-16,19-20H,12-13,17-18H2,1-4H3
|
| Chemical Name |
6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one
|
| Synonyms |
SPD-304; SPD 304; SPD304
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Water: ~100 mg/mL (~182.6 mM)
DMSO: ~50 mg/mL (~91.3 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1.25 mg/mL (2.28 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (2.28 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8261 mL | 9.1306 mL | 18.2612 mL | |
| 5 mM | 0.3652 mL | 1.8261 mL | 3.6522 mL | |
| 10 mM | 0.1826 mL | 0.9131 mL | 1.8261 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
